After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely ...
Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...
Analysts expect the New York-based company to report quarterly earnings at 46 cents per share, up from 10 cents per share in ...
The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $3.28 per share. The financial services company posted revenue of $13.01 billion in the period, which ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback